

IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the claims:

Claims 1-12 (**cancelled**).

Claim 13 (**currently amended**): A method for the production of an anti-cancer effect in a warm-blooded mammal in need thereof which comprises the administration of a VEGF receptor tyrosine kinase inhibitor in combination with a Src kinase inhibitor characterised in that:

- (i) an improved anti-cancer effect is obtained; and
- (ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced;

and wherein the VEGF receptor tyrosine kinase inhibitor is selected from:

4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline and
 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
~~and~~ or a pharmaceutically-acceptable acid-addition salts ~~salt~~ thereof;

and the Src kinase inhibitor is selected from:

4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline; and
 7-[2-(4-acetyl piperazin-1-yl) ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline ~~and~~
 7-[2-(4-acetyl piperazin-1-yl)ethoxy] 4-(5-chloro-2,3-methylenedioxy pyrid-4-ylamino)-5-isopropoxyquinazoline,
~~and~~ or a pharmaceutically-acceptable acid-addition salts ~~salt~~ thereof.

Claim 14 (**currently amended**): ~~The A~~ method according to claim 13 wherein the VEGF receptor tyrosine kinase inhibitor is 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt

thereof, and the Src kinase inhibitor is 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 15 (**currently amended**): ~~The A~~-method according to claim 13 wherein the VEGF receptor tyrosine kinase inhibitor is 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline, or a pharmaceutically acceptable acid-addition salt thereof, and the Src kinase inhibitor is 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 16 (**currently amended**): ~~The A~~-method according to claim 13 wherein, the VEGF receptor tyrosine kinase inhibitor is 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, and the Src kinase inhibitor is 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 17 (**cancelled**).

Claim 18 (**currently amended**): ~~The A~~-method according to claim 13 wherein the VEGF receptor tyrosine kinase inhibitor is 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, and the Src kinase inhibitor is 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

Claims 19-22 (**cancelled**).

Claim 23 (**currently amended**): A method for the treatment of a solid tumour disease in a warm-blooded mammal in need thereof which comprises the administration of an effective amount of a VEGF receptor tyrosine kinase inhibitor in combination with an effective amount of a Src kinase inhibitor characterised in that:

- (i) an improved anti-tumour effect is obtained; and
- (ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced;

and wherein the VEGF receptor tyrosine kinase inhibitor is selected from:

4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline and
 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
~~and~~ or a pharmaceutically-acceptable acid-addition salts ~~salt~~ thereof;

and the Src kinase inhibitor is selected from:

4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline; and
 7-[2-(4-acetylpiperazin-1-yl) ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline ~~and~~
 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxy-pyrid-4-ylamino)-5-isopropoxyquinazoline,
~~and~~ or a pharmaceutically-acceptable acid-addition salts ~~salt~~ thereof.

Claim 24 (**previously presented**): The method of claim 13 wherein the cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic and cervical cancer, Ewings tumour, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, head and neck cancer, brain cancer and renal cancer.

Claim 25 (**previously presented**): The method of claim 13 or claim 23 wherein the VEGF receptor tyrosine kinase inhibitor and the Src kinase inhibitor are administered for the treatment of a solid tumour cancer.

Claim 26 (**previously presented**): The method of claim 25 wherein the solid tumour cancer is selected from cancer of the colon, breast, prostate, lungs and skin.

Claim 27 (**previously presented**): The method of claim 13 or claim 23 wherein the VEGF receptor tyrosine kinase inhibitor and the Src kinase inhibitor are administered simultaneously, sequentially or separately.